Global Stem Cell Therapy for Osteoarthritis Market Insights and Forecast to 2028

OA is the most common degenerative joint disease. Its initial symptoms include loss of articular cartilage followed by progressive to joint stiffness, swelling, pain, and loss of mobility.
Stem cells are the body's raw materials — cells from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. These daughter cells either become new stem cells (self-renewal) or become specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells or bone cells. No other cell in the body has the natural ability to generate new cell types.
Most stem cells used for the experimental treatment of OA are adult MSCs. Researchers can easily collect them from fat or bone marrow. MSCs are able to turn into cartilage, bone, muscle, tendon, ligaments, or fat, depending on the type of tissue that surrounds them. This is why researchers are studying MSCs in stem cell treatments for OA.
Market Analysis and Insights: Global Stem Cell Therapy for Osteoarthritis Market
The global Stem Cell Therapy for Osteoarthritis market size is projected to reach US$ 107.3 million by 2028, from US$ 22 million in 2021, at a CAGR of 25.1% during 2022-2028.
In the global market, the core manufacturers of Stem cell therapy for osteoarthritis include Medipost etc, and the top 1 manufacturer accounts for about 80% of the market share. The market include Asia Pacific and Europe, with a share of 90% and 10%. allogeneic accounted for 90% and autologous accounted for 10%. the product is mainly used in primary osteoarthritis and secondary osteoarthritis fields, with a share of 92% and 8%.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Stem Cell Therapy for Osteoarthritis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Stem Cell Therapy for Osteoarthritis market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stem Cell Therapy for Osteoarthritis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stem Cell Therapy for Osteoarthritis market.
Global Stem Cell Therapy for Osteoarthritis Scope and Market Size
Stem Cell Therapy for Osteoarthritis market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Stem Cell Therapy for Osteoarthritis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Allogeneic
Autologous
Segment by Application
Primary Osteoarthritis
Secondary Osteoarthritis
By Company
Medipost
Nature Cell
Theracell Advanced Biotechnology
Takeda (TiGenix)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Frequently Asked Questions